BioPharma Resources

Drug Trial Radar · NCT03789552

Outcome Research to Confirm the Anti-anginal Effect of T89 in Patients With Stable Angina

A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group Phase 3 Study to Confirm the Safety and Efficacy of T89 in Patients With Stable Angina Pectoris, With an Extended Open-label Period to Evaluate the Long-term Safety

Last checked: Nov 19, 2026Latest source record: Apr 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 765 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

765

Planned (sponsor's estimate)

Start

Aug 1, 2019

Primary completion

Dec 2026

Study completion Mar 2027

Sponsor

Lead sponsor
Tasly Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Dec 28, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-center, double-blind, randomized, placebo-controlled, parallel-group phase 3 clinical study to confirm the safety and efficacy of T89 in patients with stable angina pectoris, with an extended open-label period to evaluate the long-term safety of T89. This study includes three main periods: the first study period is a 3-week single-blind qualifying run-in period to screen eligible stable angina patients by exercise tolerance test (ETT). The second study period is a 8-week double-blind treatment period to evaluate the efficacy and safety of T89 in patients with stable angina by ETT. And, the last study period is a 44-week open-label period to observe long-term use safety of T89.

Conditions

  • Chronic Stable Angina Pectoris

Interventions

  • T89 capsuleDrug

    T89 capsules (75mg)

  • Placebo capsuleDrug

    Placebo capsules (0mg)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in symptom-limited total exercise duration (TED) at trough drug levels on standard Bruce protocol from baseline to Day 57Time frame: Day 57 (post drug administration from randomization)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Southwest Florida Research LLC

    Naples, Florida · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.